Developer of the cancer drug perifosine, Keryx announced recently the completion of enrollment in a phase III colon cancer study, clearing the way for top-line results to be announced before the end of the year.Year to date performance: -14% Performance since June 30: -15% Driehaus Capital Management and Highland Capital Management both opened new positions in Keryx during the quarter, while Balyasny Asset Management added to an existing position that totaled 3.3 million shares at the end of June. Some small selling of Keryx occurred during the quarter from SAC Capital, Jefferies Group and Citadel Advisors.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts